Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy

Abstract Although metabolic intratumoral heterogeneity (ITH) gives important value on treatment responses and prognoses, its association with treatment outcomes have not been reported in gastric cancer (GC). We aimed to evaluate temporal changes in metabolic ITH and the associations with treatment r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shin Hye Yoo, Seo Young Kang, Jeesun Yoon, Tae-Yong Kim, Gi Jeong Cheon, Do-Youn Oh
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bd8ef7c287fb447cb0b704c266c23446
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bd8ef7c287fb447cb0b704c266c23446
record_format	dspace
spelling	oai:doaj.org-article:bd8ef7c287fb447cb0b704c266c234462021-12-02T14:12:41ZProspective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy10.1038/s41598-020-78963-22045-2322https://doaj.org/article/bd8ef7c287fb447cb0b704c266c234462021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78963-2https://doaj.org/toc/2045-2322Abstract Although metabolic intratumoral heterogeneity (ITH) gives important value on treatment responses and prognoses, its association with treatment outcomes have not been reported in gastric cancer (GC). We aimed to evaluate temporal changes in metabolic ITH and the associations with treatment responses, progression-free survival (PFS), and overall survival (OS) in advanced GC patients. Eighty-five patients with unresectable, locally advanced, or metastatic GC were prospectively enrolled before the first-line palliative chemotherapy and underwent [18F]FDG PET at baseline (TP1) and the first response follow-up evaluation (TP2). Standardized uptake values (SUVs), volumetric parameters, and textural features were evaluated in primary gastric tumor at TP1 and TP2. Of 85 patients, 44 had partial response, 33 had stable disease, and 8 progressed. From TP1 to TP2, metabolic ITH was significantly reduced (P < 0.01), and the degree of the decrease was greater in responders than in non-responders (P < 0.01). Using multiple Cox regression analyses, a low SUVmax at TP2, a high kurtosis at TP2 and larger decreases in the coefficient of variance were associated with better PFS. A low SUVmax at TP2, larger decreases in the metabolic tumor volume and larger decreased in the energy were associated with better OS. Age older than 60 years and responders also showed better OS. An early reduction in metabolic ITH is useful to predict treatment outcomes in advanced GC patients.Shin Hye YooSeo Young KangJeesun YoonTae-Yong KimGi Jeong CheonDo-Youn OhNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shin Hye Yoo Seo Young Kang Jeesun Yoon Tae-Yong Kim Gi Jeong Cheon Do-Youn Oh Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy
description	Abstract Although metabolic intratumoral heterogeneity (ITH) gives important value on treatment responses and prognoses, its association with treatment outcomes have not been reported in gastric cancer (GC). We aimed to evaluate temporal changes in metabolic ITH and the associations with treatment responses, progression-free survival (PFS), and overall survival (OS) in advanced GC patients. Eighty-five patients with unresectable, locally advanced, or metastatic GC were prospectively enrolled before the first-line palliative chemotherapy and underwent [18F]FDG PET at baseline (TP1) and the first response follow-up evaluation (TP2). Standardized uptake values (SUVs), volumetric parameters, and textural features were evaluated in primary gastric tumor at TP1 and TP2. Of 85 patients, 44 had partial response, 33 had stable disease, and 8 progressed. From TP1 to TP2, metabolic ITH was significantly reduced (P < 0.01), and the degree of the decrease was greater in responders than in non-responders (P < 0.01). Using multiple Cox regression analyses, a low SUVmax at TP2, a high kurtosis at TP2 and larger decreases in the coefficient of variance were associated with better PFS. A low SUVmax at TP2, larger decreases in the metabolic tumor volume and larger decreased in the energy were associated with better OS. Age older than 60 years and responders also showed better OS. An early reduction in metabolic ITH is useful to predict treatment outcomes in advanced GC patients.
format	article
author	Shin Hye Yoo Seo Young Kang Jeesun Yoon Tae-Yong Kim Gi Jeong Cheon Do-Youn Oh
author_facet	Shin Hye Yoo Seo Young Kang Jeesun Yoon Tae-Yong Kim Gi Jeong Cheon Do-Youn Oh
author_sort	Shin Hye Yoo
title	Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy
title_short	Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy
title_full	Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy
title_fullStr	Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy
title_full_unstemmed	Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy
title_sort	prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/bd8ef7c287fb447cb0b704c266c23446
work_keys_str_mv	AT shinhyeyoo prospectiveevaluationofmetabolicintratumoralheterogeneityinpatientswithadvancedgastriccancerreceivingpalliativechemotherapy AT seoyoungkang prospectiveevaluationofmetabolicintratumoralheterogeneityinpatientswithadvancedgastriccancerreceivingpalliativechemotherapy AT jeesunyoon prospectiveevaluationofmetabolicintratumoralheterogeneityinpatientswithadvancedgastriccancerreceivingpalliativechemotherapy AT taeyongkim prospectiveevaluationofmetabolicintratumoralheterogeneityinpatientswithadvancedgastriccancerreceivingpalliativechemotherapy AT gijeongcheon prospectiveevaluationofmetabolicintratumoralheterogeneityinpatientswithadvancedgastriccancerreceivingpalliativechemotherapy AT doyounoh prospectiveevaluationofmetabolicintratumoralheterogeneityinpatientswithadvancedgastriccancerreceivingpalliativechemotherapy
_version_	1718391807737331712

Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy

Ejemplares similares